Information on the penetration of epidermal growth factor receptor tyrosine kinase inhibitors (anti-EGFR TKIs) through the blood-brain barrier primarily comes from preclinical testing. In clinical studies, its effectiveness in patients with brain metastases can be an indicator of its penetration. However, a truly robust analysis is lacking. Until one is available, we can preliminarily evaluate the available data.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
